• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying

    6/13/24 9:10:42 AM ET
    $ASRT
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASRT alert in real time by email

    The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    Kronos Bio

    • The Trade: Kronos Bio, Inc. (NASDAQ:KRON) President and CEO Norbert W Bischofberger bought a total of 3,005,122 shares at an average price of $1.04. To acquire these shares, it cost around $3.12 million.
    • What's Happening: On May 21, Kronos Bio named Deborah Knobelman as COO and CFO.
    • What Kronos Bio Does: Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription.

    Assertio Holdings

    • The Trade: Assertio Holdings, Inc. (NASDAQ:ASRT) Director Jeff L Vacirca acquired a total of 10,000 shares at an average price of $1.11. To acquire these shares, it cost around $11,100.
    • What's Happening: On June 6, Assertio Holdings reported inducement grants under NASDAQ Listing Rule 5635(c)(4).
    • What Assertio Holdings Does: Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines.

    Nanophase Technologies

    • The Trade: Nanophase Technologies Corporation (OTC:NANX) Director R Janet Whitmore acquired a total of 18,369 shares at an average price of $1.44. The insider spent around $26,487 to buy those shares.
    • What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.
    • What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.

    Check This Out: Jim Cramer Likes This Energy Stock With 4% Yield, Recommends Buying DraftKings

    Get the next $ASRT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASRT
    $KRON

    CompanyDatePrice TargetRatingAnalyst
    Kronos Bio Inc.
    $KRON
    11/14/2024$6.00 → $1.00Overweight → Neutral
    Piper Sandler
    Kronos Bio Inc.
    $KRON
    11/14/2024Buy → Hold
    TD Cowen
    Assertio Holdings Inc.
    $ASRT
    7/26/2024$3.00Buy
    Maxim Group
    Assertio Holdings Inc.
    $ASRT
    7/3/2024$4.00Buy
    H.C. Wainwright
    Assertio Holdings Inc.
    $ASRT
    11/7/2022$7.00Buy
    Lake Street
    Kronos Bio Inc.
    $KRON
    9/14/2022$12.00Buy
    Berenberg
    Kronos Bio Inc.
    $KRON
    2/28/2022$50.00 → $30.00Overweight
    Piper Sandler
    Kronos Bio Inc.
    $KRON
    11/10/2021$35.00 → $36.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ASRT
    $KRON
    SEC Filings

    View All

    Assertio Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    1/12/26 4:44:05 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    12/22/25 4:37:55 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Assertio Holdings Inc.

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    11/21/25 5:00:38 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $KRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements

    Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with all applicable listing requirements. As of January 12, 2026, Nasdaq has determined that Assertio has regained compliance with the Minimum Bid Price Rule, which requires the Company's common stock maintains a minimum bid price of $1.00 per share for a minimum of ten consecutive days, and that the matter is now closed. Mark Reisenauer, Chief Executive Officer of Assertio: "We are pleased to have regained compliance with applicable listing requirements. Importantly, we accomplished thi

    1/12/26 4:15:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

    Peer-reviewed publication in "The Oncologist" is now available online Investigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day dosing Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an effective neutrophil recovery an

    1/9/26 1:45:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

    Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the "Certificate of Amendment") on December 19 to implement a one-for-fifteen reverse split of its issued and outstanding common stock (the "Reverse Split"). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on December 26, 2025, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on December 26, 2025. The Company's common stock will continue to trade on The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "ASRT." The new CUSIP number for the common stock follow

    12/22/25 4:30:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $KRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/19/24 9:02:18 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/15/24 2:43:25 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

    4 - Kronos Bio, Inc. (0001741830) (Issuer)

    7/1/24 8:27:32 PM ET
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $KRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, General Counsel Schlessinger Sam covered exercise/tax liability with 1,239 shares and converted options into 2,778 shares, increasing direct ownership by 12% to 14,105 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    2/20/26 6:01:14 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and COO Schwichtenberg Paul converted options into 2,778 shares and covered exercise/tax liability with 1,377 shares, increasing direct ownership by 12% to 13,410 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    2/20/26 6:00:44 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CFO Patel Ajay converted options into 2,778 shares and covered exercise/tax liability with 1,377 shares, increasing direct ownership by 10% to 15,365 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    2/20/26 6:00:13 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $KRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kronos downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Kronos from Overweight to Neutral and set a new price target of $1.00 from $6.00 previously

    11/14/24 7:43:21 AM ET
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kronos downgraded by TD Cowen

    TD Cowen downgraded Kronos from Buy to Hold

    11/14/24 7:42:59 AM ET
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Assertio Therapeutics with a new price target

    Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00

    7/26/24 7:49:44 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $KRON
    Leadership Updates

    Live Leadership Updates

    View All

    Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

    LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b

    12/17/24 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

    LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi

    12/12/24 8:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

    CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

    12/6/24 7:00:00 AM ET
    $ASRT
    $BEAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ASRT
    $KRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/14/24 3:52:50 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kronos Bio Inc.

    SC 13G/A - Kronos Bio, Inc. (0001741830) (Subject)

    11/14/24 7:58:27 AM ET
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/12/24 1:34:28 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $KRON
    Financials

    Live finance-specific insights

    View All

    Assertio Announces Leadership Transition

    Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"), effective immediately. As part of this transition, current CEO Brendan P. O'Grady will be departing the Company. Heather L. Mason, Chair of the Board of Directors, stated, "After significant del

    10/28/25 9:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025

    LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide business updates on the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcas

    8/5/25 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

    LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

    5/5/25 8:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    $KRON
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care